Differentiating haemostasis from thrombosis for therapeutic benefit

Thrombosis and Haemostasis

Volumn 110, Issue 5, 2013, Pages 859-867

  McFadyen, James D ^a   Jackson, Shaun P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Antiplatelet agents; Atherothrombosis; Thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTISENSE OLIGONUCLEOTIDE; APTAMER; BLOOD CLOTTING FACTOR 11A INHIBITOR; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 12A INHIBITIOR; BLOOD CLOTTING INHIBITOR; CD36 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 6; FIBRONECTIN; GLYCOPROTEIN; GLYCOPROTEIN IB; INTEGRIN ALPHA2B BETA3; LAMININ; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PURINERGIC P2Y RECEPTOR; SCAVENGER RECEPTOR BI; THROMBIN; THROMBOXANE A2; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 5; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BLOOD RHEOLOGY; CALCIUM SIGNALING; DYSLIPIDEMIA; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANTIPLATELET AGENTS; ATHEROTHROMBOSIS; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; HEMORRHAGE; HEMOSTASIS; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 84887001106     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0379     Document Type: Article

References (80)

1. Ross R. Atherosclerosis--an inflammatory disease. New Engl J Med 1999; 340: 115-126.
2. Goyal A, Bhatt DL, Steg PG, et al. Attained educational level and incident atherothrombotic events in low-and middle-income compared with high-income countries. Circulation 2010; 122: 1167-1175.
3. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nature Rev Drug Discov 2010; 9: 154-169.
4. Sellers MB, Tricoci P, Harrington RA. A new generation of antiplatelet agents. Curr Opin Cardiol 2009; 24: 307-312.
5. Patrono C, Baigent C, Hirsh J, et al., American College of Chest P. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 199S-233S.
6. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Acadaemic Emergency Medicine. Circulation 2007; 116: e148-304.
7. Kushner FG, Hand M, Smith SC, Jr., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
8. Fisher M, Loscalzo J. The perils of combination antithrombotic therapy and potential resolutions. Circulation 2011; 123: 232-235.
9. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 127-134.
10. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-5095.
11. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscl Thromb Vasc Biol 2007; 27: 728-739.
12. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102: 449-461.
13. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 2009; 16: 58-83.
14. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
15. Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost 1999; 82: 576-584.
16. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substratereceptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
17. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
18. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-2034.
19. Huang JS, Ramamurthy SK, Lin X, et al. Cell signalling through thromboxane A2 receptors. Cell Signal 2004; 16: 521-533.
20. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
21. Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost 1999; 82: 318-325.
22. Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338.
23. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 2022-2060.
24. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-11027.
25. Furie B, Furie BC. Mechanisms of thrombus formation. New Engl J Med 2008; 359: 938-949.
26. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscl Thromb Vasc Biol 2007; 27: 2507-2513.
27. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. Journal of thrombosis and haemostasis: J Thromb Haemost 2013; 11: 2-16.
28. Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nature Med 2009; 15: 665-673.
29. Stalker TJ, Traxler EA, Wu J, Wannemacher KM, et al. Hierarchical organization in the haemostatic response and its relationship to the platelet-signaling network. Blood 2013; 121: 1875-1885.
30. Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood 2012; 119: e45-56.
31. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007; 117: 953-960.
32. Gross PL, Furie BC, Merrill-Skoloff G, et al. Leukocyte-versus microparticlemediated tissue factor transfer during arteriolar thrombus development. J Leukocyte Biol 2005; 78: 1318-1326.
33. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115: 3355-3362.
34. Sachs UJ, Nieswandt B. In vivo thrombus formation in murine models. Circulation Res 2007; 100: 979-991.
35. Mailhac A, Badimon JJ, Fallon JT, et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 1994; 90: 988-996.
36. Wootton DM, Ku DN. Fluid mechanics of vascular systems, diseases, and thrombosis. Ann Rev Biomed Engin 1999; 1: 299-329.
37. Einav S, Bluestein D. Dynamics of blood flow and platelet transport in pathological vessels. Ann NY Acad Sci 2004; 1015: 351-366.
38. Lowe GD. Blood rheology in arterial disease. Clin Sci 1986; 71: 137-146.
39. Ruggeri ZM, Orje JN, Habermann R, et al. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108: 1903-1910.
40. Dopheide SM, Maxwell MJ, Jackson SP. Shear-dependent tether formation during platelet translocation on von Willebrand factor. Blood 2002; 99: 159-167.
41. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240.
42. Lopez JA, Dong JF. Structure and function of the glycoprotein Ib-IX-V complex. Curr Opin Hematol 1997; 4: 323-329.
43. Mazzucato M, Pradella P, Cozzi MR, et al. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. Blood 2002; 100: 2793-2800.
44. Nesbitt WS, Giuliano S, Kulkarni S, et al. Intercellular calcium communication regulates platelet aggregation and thrombus growth. J Cell Biol 2003; 160: 1151-1161.
45. Goncalves I, Nesbitt WS, Yuan Y, et al. Importance of temporal flow gradients and integrin alphaIIbbeta3 mechanotransduction for shear activation of platelets. J Biol Chem 2005; 280: 15430-15437.
46. Gillespie PG, Walker RG. Molecular basis of mechanosensory transduction. Nature 2001; 413: 194-202.
47. Nesbitt WS, Kulkarni S, Giuliano S, et al. Distinct glycoprotein Ib/V/IX and integrin alpha IIbbeta 3-dependent calcium signals cooperatively regulate platelet adhesion under flow. J Biol Chem 2002; 277: 2965-2972.
48. Marshall SJ, Senis YA, Auger JM, et al. GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood 2004; 103: 2601-2609.
49. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nature Med 2005; 11: 507-514.
50. Rathbone RL, Ardlie NG, Schwartz CJ. Platelet aggregation and thrombus formation in Diabetes Mellitus: an in vitro study. Pathology. 1970; 2: 307-316.
51. Opper C, Clement C, Schwarz H, et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 1995; 113: 211-217.
52. Terres W, Becker P, Rosenberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994; 97: 242-249.
53. Hamet P, Skuherska R, Pang SC, et al. Abnormalities of platelet function in hypertension and diabetes. Hypertension 1985; 7: II135-142.
54. Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120: 2095-2104.
55. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidaemia, oxidant stress and a prothrombotic phenotype. Nature Med 2007; 13: 1086-1095.
56. Ma Y, Ashraf MZ, Podrez EA. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidaemia. Blood 2010; 116: 1932-1941.
57. Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012; 119: 6136-6144.
58. Renne T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood 2012; 120: 4296-4303.
59. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
60. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002; 87: 774-776.
61. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
62. Suzuki J, Umeda M, Sims PJ, et al. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010; 468: 834-838.
63. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? Blood 2010; 116: 2011-2018.
64. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-666.
65. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Develop 2006; 20: 1-15.
66. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell daemise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 2006; 1757: 1371-1387.
67. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
68. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nature Rev Mol Cell Biol 2008; 9: 231-241.
69. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nature Rev Cardiol 2011; 8: 547-559.
70. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684-4692.
71. Schumacher WA, Luettgen JM, Quan ML, et al. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscl Thromb Vasc Biol 2010; 30: 388-392.
72. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-1517.
73. Smith SA, Choi SH, Collins JN, et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120: 5103-5110.
74. Ghosh A, Li W, Febbraio M, et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008; 118: 1934-1943.
75. Armstrong PC, Peter K. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost 2012; 107: 808-814.
76. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circulation Res 2006; 99: 25-33.
77. De Meyer SF, Stoll G, Wagner DD, et al. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43: 599-606.
78. Diener JL, Daniel Lagasse HA, Duerschmied D, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 2009; 7: 1155-1162.
79. Nylander S, Kull B, Bjorkman JA, et al. Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost 2012; 10: 2127-2136.
80. Yap CL, Anderson KE, Hughan SC, et al. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). Blood 2002; 99: 151-158.